BBLG

SEC source: 0001493152-26-045149 · ownership.xml · derivative · entry 1

Gagnon Robert E. · CIK 0001504983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,896

Underlying: Common Stock · 113,896 shares

Expires 2036-09-28

F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments.

SEC source: 0001493152-26-045135 · ownership.xml · derivative · entry 1

Stroever Bruce · CIK 0001657728 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,896

Underlying: Common Stock · 113,896 shares

Expires 2036-09-28

F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments.

SEC source: 0001493152-26-045147 · ownership.xml · derivative · entry 1

Angle Siddhesh Rajendra · CIK 0001889218 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,896

Underlying: Common Stock · 113,896 shares

Expires 2036-09-28

F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments.

SEC source: 0001493152-26-045140 · ownership.xml · derivative · entry 1

Meikle Phillip Terry II · CIK 0002041874 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,896

Underlying: Common Stock · 113,896 shares

Expires 2036-09-28

F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments.

SEC source: 0001493152-26-003103 · ownership.xml · derivative · entry 2

Walsh Deina H · CIK 0001651572 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,335

Underlying: Common Stock · 8,335 shares

Expires 2036-01-08

F1 · derivative.underlying_shares: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.

SEC source: 0001493152-26-003102 · ownership.xml · derivative · entry 2

Frelick Jeff · CIK 0001645093 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,668

Underlying: Common Stock · 16,668 shares

Expires 2036-01-08

F1 · derivative.underlying_shares: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.

SEC source: 0001641172-25-014099 · ownership.xml · derivative · entry 1

Meikle Phillip Terry II · CIK 0002041874 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,894

Underlying: Common Stock · 62,894 shares

Expires 2035-06-04

F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests in four equal quarterly installments.

SEC source: 0001641172-25-014100 · ownership.xml · derivative · entry 1

Stroever Bruce · CIK 0001657728 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,894

Underlying: Common Stock · 62,894 shares

Expires 2035-06-04

F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests in four equal quarterly installments.

SEC source: 0001641172-25-014097 · ownership.xml · derivative · entry 1

Angle Siddhesh Rajendra · CIK 0001889218 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,894

Underlying: Common Stock · 62,894 shares

Expires 2035-06-04

F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests in four equal quarterly installments.

SEC source: 0001641172-25-014098 · ownership.xml · derivative · entry 1

Gagnon Robert E. · CIK 0001504983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,894

Underlying: Common Stock · 62,894 shares

Expires 2035-06-04

F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests in four equal quarterly installments.

SEC source: 0001493152-25-002880 · ownership.xml · derivative · entry 2

Walsh Deina H · CIK 0001651572 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,055

Underlying: Common Stock · 27,055 shares

Expires 2027-01-15

F1 · derivative.underlying_shares: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.

SEC source: 0001493152-25-002884 · ownership.xml · derivative · entry 2

Frelick Jeff · CIK 0001645093 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,110

Underlying: Common Stock · 54,110 shares

Expires 2027-01-15

F1 · derivative.underlying_shares: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice,vests and becomes exercisable immediately.

SEC source: 0001493152-24-041658 · ownership.xml · derivative · entry 2

Meikle Phillip Terry II · CIK 0002041874 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,185

Underlying: Common Stock · 28,185 shares

Expires 2034-10-16

F2 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vesting and becoming exercisable in four equal installments on 12/17/24, 3/19/25, 6/19/25 and 9/17/25.

SEC source: 0001493152-24-041658 · ownership.xml · derivative · entry 1

Meikle Phillip Terry II · CIK 0002041874 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9

Underlying: Common Stock · 9 shares

Expires 2034-10-16

F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable on the date of the next annual meeting of the stockholders of the Company following the grant date.

SEC source: 0001493152-24-037222 · ownership.xml · derivative · entry 1

Stroever Bruce · CIK 0001657728 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,713

Underlying: Common Stock · 30,713 shares

Expires 2034-09-17

F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable quarterly through the date of the next annual meeting of stockholders of the Company.

SEC source: 0001493152-24-037220 · ownership.xml · derivative · entry 1

Gagnon Robert E. · CIK 0001504983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,713

Underlying: Common Stock · 30,713 shares

Expires 2034-09-17

F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable quarterly through the date of the next annual meeting of stockholders of the Company.

SEC source: 0001493152-24-037218 · ownership.xml · derivative · entry 1

Angle Siddhesh Rajendra · CIK 0001889218 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,713

Underlying: Common Stock · 30,713 shares

Expires 2034-09-17

F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable quarterly through the date of the next annual meeting of stockholders of the Company.

SEC source: 0001493152-24-003099 · ownership.xml · derivative · entry 2

Walsh Deina H · CIK 0001651572 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2026-01-17

F1 · derivative.underlying_shares: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.

SEC source: 0001493152-24-003097 · ownership.xml · derivative · entry 2

Frelick Jeff · CIK 0001645093 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2026-01-17

F1 · derivative.underlying_shares: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.

SEC source: 0001493152-24-001971 · ownership.xml · derivative · entry 2

Gagnon Robert E. · CIK 0001504983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,015

Underlying: Common Stock · 8,006 shares

Expires 2034-01-08

F2 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, 2,003 options are immediately exercisable with the remaining 6,003 options vesting and becoming exercisable in three equal installments on 3/12/2024, 6/12/2024, and 9/12/2024.

SEC source: 0001493152-24-001971 · ownership.xml · derivative · entry 1

Gagnon Robert E. · CIK 0001504983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9

Underlying: Common Stock · 9 shares

Expires 2034-01-08

F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable on the date of the next annual meeting of the stockholders of the Company following the grant date.

SEC source: 0001493152-23-033177 · ownership.xml · derivative · entry 1

Lucera Erick · CIK 0001697616 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,763

Underlying: Common Stock · 85,763 shares

Expires 2033-09-13

F1 · derivative.exercise_date: Vests quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.

SEC source: 0001493152-23-033176 · ownership.xml · derivative · entry 1

Angle Siddhesh Rajendra · CIK 0001889218 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,763

Underlying: Common Stock · 85,763 shares

Expires 2033-09-13

F1 · derivative.exercise_date: Vests quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.

SEC source: 0001493152-23-033175 · ownership.xml · derivative · entry 1

Stroever Bruce · CIK 0001657728 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,763

Underlying: Common Stock · 85,763 shares

Expires 2033-09-13

F1 · derivative.exercise_date: Vests quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.

SEC source: 0001493152-23-032583 · ownership.xml · nonDerivative · entry 1

Walsh Deina H · CIK 0001651572 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

SEC source: 0001493152-23-032321 · ownership.xml · nonDerivative · entry 1

Frelick Jeff · CIK 0001645093 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,204

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6799 to $0.6898, inclusive. Mr. Frelick undertakes to provide Bone Biologics Corporation, any security holder of Bone Biologics Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001493152-23-031935 · ownership.xml · nonDerivative · entry 2

Walsh Deina H · CIK 0001651572 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,000

SEC source: 0001493152-23-031935 · ownership.xml · nonDerivative · entry 1

Walsh Deina H · CIK 0001651572 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300

SEC source: 0001493152-23-031680 · ownership.xml · nonDerivative · entry 1

Frelick Jeff · CIK 0001645093 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,704

F1 · balance_after: Includes 104 shares of vested restricted stock that were inadvertently reported in Table II at the time of grant.

SEC source: 0001493152-23-009491 · ownership.xml · derivative · entry 13

Hankey Don · CIK 0001561288 · Director · Chairman of the Board · 10% owner

Knight Insurance Company, Ltd · CIK 0001971547 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Knight Specialty Insurance Company

Disclosed balance after: 37,918

Underlying: Common · 37,918 shares

Expires 2026-10-13

F1 · kind: On March 27, 2023, Hankey Capital LLC transferred an aggregate of 7,043,801 shares and 476,190 shares issuable upon exercise of warrants of the Company as follows: a. Don Hankey Trust, Related Party, 4,153,065 shares, 280,764 warrants b. Knight Services, Inc, Related Party, 77,681 shares, 5,252 warrants c. Knight Insurance Company, Ltd., Related Party, 1,466,603 shares, 99,148 warrants d. Knightbrook Insurance Company, Related Party, 285,438 shares, 19,297 warrants e. Knight Specialty Insurance Company, Related Party, 560,877 shares, 37,918 warrants f. Unrelated Parties, 500,137 shares, 33,811 warrants

SEC source: 0001493152-23-009491 · ownership.xml · derivative · entry 12

Hankey Don · CIK 0001561288 · Director · Chairman of the Board · 10% owner

Knight Insurance Company, Ltd · CIK 0001971547 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Knightbrook Insurance Company

Disclosed balance after: 19,297

Underlying: Common · 19,297 shares

Expires 2026-10-13

F1 · kind: On March 27, 2023, Hankey Capital LLC transferred an aggregate of 7,043,801 shares and 476,190 shares issuable upon exercise of warrants of the Company as follows: a. Don Hankey Trust, Related Party, 4,153,065 shares, 280,764 warrants b. Knight Services, Inc, Related Party, 77,681 shares, 5,252 warrants c. Knight Insurance Company, Ltd., Related Party, 1,466,603 shares, 99,148 warrants d. Knightbrook Insurance Company, Related Party, 285,438 shares, 19,297 warrants e. Knight Specialty Insurance Company, Related Party, 560,877 shares, 37,918 warrants f. Unrelated Parties, 500,137 shares, 33,811 warrants

SEC source: 0001493152-23-009491 · ownership.xml · derivative · entry 11

Hankey Don · CIK 0001561288 · Director · Chairman of the Board · 10% owner

Knight Insurance Company, Ltd · CIK 0001971547 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Knight Insurance Company, Ltd.

Disclosed balance after: 99,148

Underlying: Common · 99,148 shares

Expires 2026-10-13

F1 · kind: On March 27, 2023, Hankey Capital LLC transferred an aggregate of 7,043,801 shares and 476,190 shares issuable upon exercise of warrants of the Company as follows: a. Don Hankey Trust, Related Party, 4,153,065 shares, 280,764 warrants b. Knight Services, Inc, Related Party, 77,681 shares, 5,252 warrants c. Knight Insurance Company, Ltd., Related Party, 1,466,603 shares, 99,148 warrants d. Knightbrook Insurance Company, Related Party, 285,438 shares, 19,297 warrants e. Knight Specialty Insurance Company, Related Party, 560,877 shares, 37,918 warrants f. Unrelated Parties, 500,137 shares, 33,811 warrants

SEC source: 0001493152-23-009491 · ownership.xml · derivative · entry 10

Hankey Don · CIK 0001561288 · Director · Chairman of the Board · 10% owner

Knight Insurance Company, Ltd · CIK 0001971547 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Knight Services, Inc

Disclosed balance after: 5,252

Underlying: Common · 5,252 shares

Expires 2026-10-13

F1 · kind: On March 27, 2023, Hankey Capital LLC transferred an aggregate of 7,043,801 shares and 476,190 shares issuable upon exercise of warrants of the Company as follows: a. Don Hankey Trust, Related Party, 4,153,065 shares, 280,764 warrants b. Knight Services, Inc, Related Party, 77,681 shares, 5,252 warrants c. Knight Insurance Company, Ltd., Related Party, 1,466,603 shares, 99,148 warrants d. Knightbrook Insurance Company, Related Party, 285,438 shares, 19,297 warrants e. Knight Specialty Insurance Company, Related Party, 560,877 shares, 37,918 warrants f. Unrelated Parties, 500,137 shares, 33,811 warrants

SEC source: 0001493152-23-009491 · ownership.xml · derivative · entry 9

Hankey Don · CIK 0001561288 · Director · Chairman of the Board · 10% owner

Knight Insurance Company, Ltd · CIK 0001971547 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Don Hankey Trust

Disclosed balance after: 280,764

Underlying: Common · 280,764 shares

Expires 2026-10-13

F1 · kind: On March 27, 2023, Hankey Capital LLC transferred an aggregate of 7,043,801 shares and 476,190 shares issuable upon exercise of warrants of the Company as follows: a. Don Hankey Trust, Related Party, 4,153,065 shares, 280,764 warrants b. Knight Services, Inc, Related Party, 77,681 shares, 5,252 warrants c. Knight Insurance Company, Ltd., Related Party, 1,466,603 shares, 99,148 warrants d. Knightbrook Insurance Company, Related Party, 285,438 shares, 19,297 warrants e. Knight Specialty Insurance Company, Related Party, 560,877 shares, 37,918 warrants f. Unrelated Parties, 500,137 shares, 33,811 warrants

SEC source: 0001493152-23-009491 · ownership.xml · derivative · entry 8

Hankey Don · CIK 0001561288 · Director · Chairman of the Board · 10% owner

Knight Insurance Company, Ltd · CIK 0001971547 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Hankey Capital, LLC

Disclosed balance after: 0

Underlying: Common · 33,811 shares

Expires 2026-10-13

F1 · kind: On March 27, 2023, Hankey Capital LLC transferred an aggregate of 7,043,801 shares and 476,190 shares issuable upon exercise of warrants of the Company as follows: a. Don Hankey Trust, Related Party, 4,153,065 shares, 280,764 warrants b. Knight Services, Inc, Related Party, 77,681 shares, 5,252 warrants c. Knight Insurance Company, Ltd., Related Party, 1,466,603 shares, 99,148 warrants d. Knightbrook Insurance Company, Related Party, 285,438 shares, 19,297 warrants e. Knight Specialty Insurance Company, Related Party, 560,877 shares, 37,918 warrants f. Unrelated Parties, 500,137 shares, 33,811 warrants

SEC source: 0001493152-23-009491 · ownership.xml · nonDerivative · entry 1

Hankey Don · CIK 0001561288 · Director · Chairman of the Board · 10% owner

Knight Insurance Company, Ltd · CIK 0001971547 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Hankey Capital, LLC

Disclosed balance after: 0

F1 · kind: On March 27, 2023, Hankey Capital LLC transferred an aggregate of 7,043,801 shares and 476,190 shares issuable upon exercise of warrants of the Company as follows: a. Don Hankey Trust, Related Party, 4,153,065 shares, 280,764 warrants b. Knight Services, Inc, Related Party, 77,681 shares, 5,252 warrants c. Knight Insurance Company, Ltd., Related Party, 1,466,603 shares, 99,148 warrants d. Knightbrook Insurance Company, Related Party, 285,438 shares, 19,297 warrants e. Knight Specialty Insurance Company, Related Party, 560,877 shares, 37,918 warrants f. Unrelated Parties, 500,137 shares, 33,811 warrants

SEC source: 0001493152-23-006965 · ownership.xml · derivative · entry 1

Walsh Deina H · CIK 0001651572 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,875

Underlying: Common Stock · 18,875 shares

Expires 2025-01-25

SEC source: 0001493152-23-006968 · ownership.xml · derivative · entry 1

Frelick Jeff · CIK 0001645093 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,140

Underlying: Common Stock · 37,750 shares

Expires 2025-01-25

SEC source: 0001493152-23-006969 · ownership.xml · derivative · entry 1

Stroever Bruce · CIK 0001657728 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,516

Underlying: Common Stock · 36,845 shares

Expires 2027-08-23

F1 · derivative.exercise_date: Quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.

SEC source: 0001493152-23-006967 · ownership.xml · derivative · entry 1

Angle Siddhesh Rajendra · CIK 0001889218 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,516

Underlying: Common Stock · 36,845 shares

Expires 2027-08-23

F1 · derivative.exercise_date: Quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.

SEC source: 0001493152-23-006966 · ownership.xml · derivative · entry 1

Lucera Erick · CIK 0001697616 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,516

Underlying: Common Stock · 36,845 shares

Expires 2027-08-23

F1 · derivative.exercise_date: Quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.

SEC source: 0001493152-22-005547 · ownership.xml · derivative · entry 1

Walsh Deina H · CIK 0001651572 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2025-01-03

SEC source: 0001493152-22-005548 · ownership.xml · derivative · entry 1

Frelick Jeff · CIK 0001645093 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,389

Underlying: Common Stock · 50,000 shares

Expires 2025-01-01

SEC source: 0001493152-22-005546 · ownership.xml · derivative · entry 2

Angle Siddhesh Rajendra · CIK 0001889218 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,671

Underlying: Common Stock · 8,722 shares

Expires 2032-01-01

F1 · derivative.exercise_date: Quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.

SEC source: 0001493152-22-005545 · ownership.xml · derivative · entry 2

Stroever Bruce · CIK 0001657728 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,671

Underlying: Common Stock · 8,722 shares

Expires 2032-01-01

F1 · derivative.exercise_date: Quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.

SEC source: 0001493152-22-005543 · ownership.xml · derivative · entry 2

Lucera Erick · CIK 0001697616 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,671

Underlying: Common Stock · 8,722 shares

Expires 2032-01-01

F1 · derivative.exercise_date: Quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.

SEC source: 0001493152-22-005546 · ownership.xml · derivative · entry 1

Angle Siddhesh Rajendra · CIK 0001889218 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,949

Underlying: Common Stock · 2,949 shares

Expires 2031-10-26

SEC source: 0001493152-22-005545 · ownership.xml · derivative · entry 1

Stroever Bruce · CIK 0001657728 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,949

Underlying: Common Stock · 2,949 shares

Expires 2031-10-26

SEC source: 0001493152-22-005543 · ownership.xml · derivative · entry 1

Lucera Erick · CIK 0001697616 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,949

Underlying: Common Stock · 2,949 shares

Expires 2031-10-26

SEC source: 0001493152-21-025816 · ownership.xml · derivative · entry 5

Hankey Don · CIK 0001561288 · Director · Chairman of the Board · 10% owner

HANKEY CAPITAL, LLC · CIK 0001675964 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hankey Capital, LLC

Disclosed balance after: 476,190

Underlying: Common · 476,190 shares

Expires 2026-10-13

F3 · price: Represents shares purchased in the Issuer's public offering of units, with each unit consisting of one share of Common Stock and one Warrant. The allocation of a unit is $5.24 for a common share, and $0.01 for a warrant.